Table S5. Sensitivity analysis of OSs and RCTs in recurrent VTE.

Omitted studies	RR (95%CI)
OSs
Alzghari 2018	0.74 (0.64–0.86)
Chaudhury 2018	0.74 (0.64–0.86)
Ross 2017	0.74 (0.63–0.86)
Signorelli 2017	0.74 (0.63–0.86)
Nicklaus 2018	0.74 (0.63–0.86)
Phelps 2019	0.73 (0.63–0.85)
Simmons 2018	0.74 (0.64–0.86)
Streiff 2018	0.73 (0.60–0.90)
Pritchard 2019	0.73 (0.63–0.85)
RCTs
SELECT-D	0.68 (0.50–0.93)
Hokusai-Cancer	0.59 (0.38–0.91)
AMPLIFY	0.65 (0.49–0.87)
EINSTEIN-PE/DVT	0.65 (0.48–0.87)
Hokusai-VTE	0.66 (0.49–0.88)
RECOVER-I/II	0.63 (0.46–0.86)

RCTs, randomized controlled trials; OSs, observational studies; VTE, venous thromboembolism; RR, relative risk.